SourceBio International PLC Result of AGM (8349B)

TIDMSBI

RNS Number : 8349B

SourceBio International PLC

14 June 2021

14 June 2021

SourceBio International plc

('SourceBio')

RESULT OF ANNUAL GENERAL MEETING

SourceBio confirms that all resolutions put to the 2021 Annual General Meeting held on the 14 June were

duly passed by the required majority.

Voting on the resolutions was as follows:

 
 Resolution   Description                                         For   Against   Withheld 
              To receive and approve the Company's 
               Annual Report and Accounts for 
               the financial year ended 31 December 
               2020 together with the Directors' 
               Report (including the Strategic 
 1             Report) and the Auditor's Report.           58,529,422       802        400 
             -------------------------------------------  -----------  --------  --------- 
              To receive and approve the Directors' 
               Remuneration Report for the financial 
               year ended 31 December 2020, excluding 
               the proposed remuneration policy, 
               executive share options plan and 
 2             Save As You Earn ("SAYE") scheme.           58,523,385     7,239        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To approve the proposed remuneration 
               policy expected to be applied 
 3             in 2021.                                    57,772,392     8,232    750,000 
             -------------------------------------------  -----------  --------  --------- 
              To approve the establishment and 
               implementation of a proposed executive 
 4             share options plan.                         57,767,232     8,392    755,000 
             -------------------------------------------  -----------  --------  --------- 
              To approve the establishment and 
               implementation of a proposed SAYE 
 5             scheme.                                     58,527,668     1,556      1,400 
             -------------------------------------------  -----------  --------  --------- 
              To re-elect Jay LeCoque (Executive 
               Chairman) as a Director of the 
 6             Company.                                    58,529,756       868        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To re-elect Tony Ratcliffe (Chief 
               Financial Officer) as a Director 
 7             of the Company.                             58,530,624       Nil        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To re-elect Sir Ian Carruthers 
               (Senior Independent Non-Executive 
               Director) as a Director of the 
 8             Company.                                    58,526,545     3,748        331 
             -------------------------------------------  -----------  --------  --------- 
              To re-elect Simon Constantine 
               (Independent Non-Executive Director) 
 9             as a Director of the Company.               58,529,091     1,533        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To re-elect Marco Fumagalli (Non-Executive 
               Director) as a Director of the 
 10            Company.                                    58,529,956       668        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To re-elect Christopher Mills 
               (Non-Executive Director) as a 
 11            Director of the Company.                    58,528,891     1,733        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To re-appoint RSM UK Audit LLP 
               as auditor of the Company and 
               to authorise the Directors to 
 12            fix their remuneration.                     58,529,024     1,600        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To authorise the Directors generally 
               to allot ordinary shares up to 
 13            the specified limit.                        58,524,551     5,673        400 
             -------------------------------------------  -----------  --------  --------- 
              To empower the Directors to issue 
               shares free from statutory pre-emption 
 14 *          rights up to the specified limit.           58,518,215    12,409        Nil 
             -------------------------------------------  -----------  --------  --------- 
              To authorise amendment to the 
 15 *          Company's Articles of Association.          58,524,345     1,279      5,000 
             -------------------------------------------  -----------  --------  --------- 
 

* Special Resolution

A trading update was released at 7.00am this morning.

Notes:

-- Any proxy appointments which gave direction to the Executive Chairman have been included in the "for" column;

   --    The total number of shares in issue is 74,183,038 

Contacts :

 
 SourceBio International plc                                 www.sourcebiointernational.com 
 Jay LeCoque, Executive Chairman                                            Via Walbrook PR 
 Tony Ratcliffe, Chief Financial Officer 
 
 Liberum (Nominated Advisor and Broker)                                  Tel: [phone] 
 Bidhi Bhoma 
  Richard Lindley 
 Euan Brown 
 
 Walbrook PR Limited                         Tel: [phone] or [e-mail] 
 Paul McManus / Sam Allen                                        Mob: [phone] / 07502 
                                                                                    558 258 
 
 

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products with clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:

-- Infectious Disease Testing - a range of COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and the DHSC. Utilising multiple technologies, SourceBio offers screening, gold standard RT-PCR and whole genome sequencing COVID-19 testing solutions and operates under ISO 15189 accreditation required by the DHSC. SourceBio also provides employee testing solutions to industry, direct to consumer home test kits (including 'Fit to Fly', 'Test to Release' and '2 & 8 Day International Travel' approved tests) whilst also being the lead operator on mobile testing unit services to support outbreak testing for the DHSC, event and venue testing.

-- Healthcare Diagnostics - histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.

-- Genomics - DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.

-- Stability Storage - shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA.

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUSVURAAUNAAR

(END) Dow Jones Newswires

June 14, 2021 09:08 ET (13:08 GMT)